5-(N,N-dimethyl)-Amiloride Hydrochloride: Potent NHE1 Inhibitor for Cardiovascular and Endothelial Research

Executive Summary: 5-(N,N-dimethyl)-Amiloride (hydrochloride) (DMA) is a selective Na+/H+ exchanger inhibitor with nanomolar potency, especially for the NHE1 isoform (Ki = 0.02 µM) (APExBIO). DMA has demonstrated protection against cardiac ischemia-reperfusion injury by normalizing sodium levels and preserving contractility (Chen et al., 2021). DMA minimally affects NHE4, NHE5, and NHE7, making it highly selective. The compound inhibits ouabain-sensitive ATPase activity in rat liver plasma membranes, implicating broader metabolic effects. Research using DMA provides mechanistic insight into Na+/H+ exchanger signaling relevant to cardiovascular and endothelial injury models.

Biological Rationale

The Na+/H+ exchanger (NHE) family regulates intracellular pH and cell volume by exchanging intracellular protons for extracellular sodium ions. NHE1 is the most widely expressed isoform in mammalian cells, including cardiac myocytes and vascular endothelial cells (Chen et al., 2021). Proper NHE1 function is essential for maintaining cellular homeostasis, especially under stress conditions such as hypoxia or inflammation. Dysregulation of NHE1 activity contributes to pathologies including ischemia-reperfusion injury, cardiac contractile dysfunction, and endothelial barrier disruption. Moesin (MSN), an endothelial biomarker, is upregulated in sepsis and linked to NHE1-mediated signaling and cell permeability (Chen et al., 2021). Inhibitors like 5-(N,N-dimethyl)-Amiloride enable targeted interrogation of these signaling pathways in translational models. For further mechanistic context, see this advanced overview, which this article extends by directly linking NHE inhibition to endothelial injury biomarker research.

Mechanism of Action of 5-(N,N-dimethyl)-Amiloride (hydrochloride)

DMA is a structural derivative of amiloride, modified at the 5-position with N,N-dimethyl groups, increasing potency and selectivity for NHE isoforms. Its primary mechanism involves competitive inhibition of the Na+/H+ exchange process on the cytoplasmic membrane. Quantified inhibition constants (Ki) are 0.02 µM for NHE1, 0.25 µM for NHE2, and 14 µM for NHE3, with negligible effect on NHE4, NHE5, and NHE7 (APExBIO). DMA blocks proton extrusion and sodium uptake, resulting in intracellular acidification and altered sodium homeostasis. In cardiac tissue, reduced NHE1 activity by DMA limits sodium and calcium overload during ischemia-reperfusion, thereby protecting contractile function. DMA also inhibits ouabain-sensitive ATPase activity, implicating effects on ion-motive ATPases involved in cell metabolism. See this analysis for additional mechanistic insights, which this article updates with recent selectivity and translational data.

Evidence & Benchmarks

• DMA inhibits NHE1 with a Ki of 0.02 µM in mammalian cells (APExBIO).
• DMA demonstrates cardioprotection in ischemia-reperfusion models by preventing sodium overload and preserving contractility (Chen et al., 2021).
• DMA reduces alanine uptake and ouabain-sensitive ATP hydrolysis in rat hepatocytes, indicating broader impact on ion transport and metabolism (Chen et al., 2021).
• DMA has minimal inhibitory effects on NHE4, NHE5, and NHE7, supporting its selectivity profile (APExBIO).
• DMA is soluble up to 30 mg/ml in DMSO and dimethyl formamide, enabling robust experimental workflows (APExBIO).
• Moesin upregulation in sepsis correlates with endothelial permeability, a process mechanistically linked to NHE1 signaling (Chen et al., 2021).

Applications, Limits & Misconceptions

Applications: DMA is widely used in research on:

• Cardiovascular disease mechanisms, especially ischemia-reperfusion injury and contractile dysfunction (APExBIO).
• Dissecting Na+/H+ exchanger signaling in endothelial and epithelial cell models (detailed here; this article clarifies the connection to sepsis biomarker research).
• Exploring intracellular pH regulation and its impact on cell metabolism and ion transport.
• Developing translational models for endothelial injury, sepsis, and tissue barrier function.

Limits: DMA is not approved for diagnostic or therapeutic use in humans. Its specificity is limited to NHE1, NHE2, and NHE3 isoforms at relevant concentrations. Long-term solution stability is poor; fresh preparations are required for each experiment. Effects in non-mammalian models are not fully validated.

Common Pitfalls or Misconceptions

• DMA is not suitable as a clinical treatment: It is strictly for research use and lacks clinical safety data (APExBIO).
• DMA does not inhibit all NHE isoforms equally: NHE4, NHE5, and NHE7 are minimally affected at standard concentrations.
• DMA is not stable in solution long term: Freshly prepared solutions are required for reliable results.
• DMA efficacy is cell-type and species dependent: Most evidence is from mammalian models.
• DMA's effects on ATPase activity do not generalize to all ion pumps: Its primary targets are ouabain-sensitive ATPases in rat liver.

Workflow Integration & Parameters

DMA is supplied as a crystalline solid and should be stored at -20°C. It is soluble up to 30 mg/ml in DMSO and dimethyl formamide. For experimental workflows, DMA is typically prepared fresh prior to use due to limited solution stability. Standard working concentrations range from 0.01 µM to 10 µM, depending on cell type and NHE isoform selectivity. In cardiac or endothelial model systems, DMA is added directly to cell culture or perfused tissues for acute inhibition studies. For mechanistic studies involving endothelial permeability or sepsis biomarker readouts, DMA is applied in parallel with inflammatory or hypoxic challenges. The C3505 kit from APExBIO provides detailed solubility and handling instructions. For a systems-level workflow guide, see this resource, which this article supplements with direct integration steps for endothelial injury models.

Conclusion & Outlook

5-(N,N-dimethyl)-Amiloride hydrochloride is a high-affinity, selective NHE1 inhibitor enabling advanced research in sodium ion transport, pH regulation, and cardiovascular disease mechanisms. Its use has clarified the role of NHE1 in ischemia-reperfusion injury and in the modulation of endothelial biomarkers such as moesin. While robust for in vitro and ex vivo models, DMA is not intended for clinical use. Ongoing research with DMA will advance understanding of Na+/H+ exchanger signaling in cardiovascular and inflammatory pathologies. For additional context on translational model development, see this recent review, which this article updates with specific application caveats and new mechanistic data.